Abstract. In the 2015 winter month of December, northern China witnessed the most severe air pollution phenomena since the 2013 winter haze events occurred. This triggered the first-ever red alert in the air pollution control history of Beijing, with an instantaneous fine particulate matter (PM2. 5) concentration over 1 mg m−3. Air quality observations reveal large temporal–spatial variations in PM2. 5 concentrations over the Beijing–Tianjin–Hebei (Jing-Jin-Ji) area between 2014 and 2015. Compared to 2014, the PM2. 5 concentrations over the area decreased significantly in all months except November and December of 2015, with an increase of 36 % in December. Analysis shows that the PM2. 5 concentrations are significantly correlated with the local meteorological parameters in the Jing-Jin-Ji area such as the stable conditions, relative humidity (RH), and wind field. A comparison of two month simulations (December 2014 and 2015) with the same emission data was performed to explore and quantify the meteorological impacts on the PM2. 5 over the Jing-Jin-Ji area. Observation and modeling results show that the worsening meteorological conditions are the main reasons behind this unusual increase of air pollutant concentrations and that the emission control measures taken during this period of time have contributed to mitigate the air pollution ( ∼ 9 %) in the region. This work provides a scientific insight into the emission control measures vs. the meteorology impacts for the period.
Metastatic cancers require further diagnosis to determine their primary tumor sites. However, the tissue-of-origin for around 5% tumors could not be identified by routine medical diagnosis according to a statistics in the United States. With the development of machine learning techniques and the accumulation of big cancer data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), it is now feasible to predict cancer tissue-of-origin by computational tools. Metastatic tumor inherits characteristics from its tissue-of-origin, and both gene expression profile and somatic mutation have tissue specificity. Thus, we developed a computational framework to infer tumor tissue-of-origin by integrating both gene mutation and expression (TOOme). Specifically, we first perform feature selection on both gene expressions and mutations by a random forest method. The selected features are then used to build up a multi-label classification model to infer cancer tissue-of-origin. We adopt a few popular multiplelabel classification methods, which are compared by the 10-fold cross validation process. We applied TOOme to the TCGA data containing 7,008 non-metastatic samples across 20 solid tumors. Seventy four genes by gene expression profile and six genes by gene mutation are selected by the random forest process, which can be divided into two categories: (1) cancer type specific genes and (2) those expressed or mutated in several cancers with different levels of expression or mutation rates. Function analysis indicates that the selected genes are significantly enriched in gland development, urogenital system development, hormone metabolic process, thyroid hormone generation prostate hormone generation and so on. According to the multiple-label classification method, random forest performs the best with a 10-fold cross-validation prediction accuracy of 96%. We also use the 19 metastatic samples from TCGA and 256 cancer samples downloaded from GEO as independent testing data, for which TOOme achieves a prediction accuracy of 89%. The cross-validation validation accuracy is better than those using gene expression (i.e., 95%) and gene
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.